A new treatment option for patients with advanced non-small-cell lung cancer (NSCLC) harboring a KRASG12C mutation is on the horizon.Read More
New research reinforces the safety and efficacy of combination treatment with nivolumab, gemcitabine and cisplatin in patients with muscle-invasive bladder cancer.
New research favors MRI for assessing the extent of disease in patients with invasive lobular carcinoma, a distinct subset of cancer that is notoriously difficult to stage.
A radiation oncologist and surgeon discuss how partial breast irradiation, novel tissue markers and deep inspiratory breath holds fit into Cleveland Clinic’s breast cancer radiation protocols.
Preliminary results from the phase 3 ADAURA trial indicate that osimertinib is superior to placebo in adjuvant treatment of EGFR-mutated non-small cell lung cancer.
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services Policy
The phase 3 SWOG S1216 trial has set a new benchmark for survival estimates for metastatic hormone-sensitive prostate cancer patients who have access to multiple approved subsequent life-prolonging therapies.
The immune checkpoint inhibitor and anti-PD-L1 monoclonal antibody pembrolizumab improves relapse-free survival but not overall survival when compared with other adjuvant treatments for patients with high-risk resected melanoma.
A national trial will seek to determine whether maintenance therapy with avelumab and a VEGF tyrosine kinase inhibitor can improve survival among patients with urothelial cancer.
Learn more about examples of groundbreaking research and new medical and surgical approaches that are leading the way in prostate cancer care.
Analysis of a multi-institutional cohort of patients with lobular breast cancer provides key insights into prognosis.
A patient opts for a novel clinical trial and thrives with stage 4 colorectal cancer.